Since the prevalence of HER-positivity in Costa Rica is not known, the anti-HER2 agents have not been employed so far for the treatment of GC, which means that HER2-positive GC patients are not deriving clinical benefit from these pharmacological agents. The gene discussed is ERBB2; the disease is gastric cancer.